An existing biotechnology venture is seeking an infusion of $5 million to carry it to the next milestone. The company has a prototype of a device for using ultrasound to shatter kidney stones. The $5 million is needed to complete the testing required for FDA approval. An investor is proposing to provide the capital in exchange for 2 million shares of common stock. Alternatively, the investor will accept 1.8 million shares of preferred stock, convertible to common on a 1 for 1 basis, or the investor will accept 1.5 million convertible preferred shares, along with warrants to acquire an additional 1.5 million shares for a nominal price. The warrants can only be exercised if the venture fails to achieve the revenue level projected by the entrepreneur two years after the investment. In any case, the entrepreneur would own 2.5 million shares of common stock. Compute the pre- and post-money valuations for each scenario. If you were the entrepreneur, what factors would you want to consider in deciding which of the offers to accept? If you were the investor, how would you interpret the entrepreneur's choice?